\BOOKMARK [0][]{chapter*.5}{List\040of\040Figures}{}% 1
\BOOKMARK [0][]{chapter*.6}{List\040of\040Tables}{}% 2
\BOOKMARK [0][]{chapter.1}{1\040Background}{}% 3
\BOOKMARK [1][]{section.1.1}{1.1\040Cancer\040metabolism}{chapter.1}% 4
\BOOKMARK [2][]{subsection.1.1.1}{1.1.1\040Metabolism\040switch\040in\040quiescent\040vs\040proliferative\040cell}{section.1.1}% 5
\BOOKMARK [2][]{subsection.1.1.2}{1.1.2\040Signaling\040in\040metabolism\040reprogramming}{section.1.1}% 6
\BOOKMARK [1][]{section.1.2}{1.2\040Liver\040metabolism}{chapter.1}% 7
\BOOKMARK [2][]{subsection.1.2.1}{1.2.1\040Liver\040glucose\040regulation}{section.1.2}% 8
\BOOKMARK [2][]{subsection.1.2.2}{1.2.2\040Liver\040lipid\040metabolism}{section.1.2}% 9
\BOOKMARK [1][]{section.1.3}{1.3\040PP2A\040and\040its\040biology}{chapter.1}% 10
\BOOKMARK [2][]{subsection.1.3.1}{1.3.1\040PP2A\040structure}{section.1.3}% 11
\BOOKMARK [2][]{subsection.1.3.2}{1.3.2\040PP2A\040in\040signaling}{section.1.3}% 12
\BOOKMARK [1][]{section.1.4}{1.4 Aim of study–PPP2R5C}{chapter.1}% 13
\BOOKMARK [0][]{chapter.2}{2\040Results}{}% 14
\BOOKMARK [1][]{section.2.1}{2.1\040Transcriptional\040change\040of\040PPP2R5C}{chapter.2}% 15
\BOOKMARK [2][]{subsection.2.1.1}{2.1.1\040PPP2R5C\040splicing\040isoforms}{section.2.1}% 16
\BOOKMARK [2][]{subsection.2.1.2}{2.1.2\040Transcriptional\040change\040of\040PPP2R5C\040in\040response\040to\040metabolic\040state}{section.2.1}% 17
\BOOKMARK [2][]{subsection.2.1.3}{2.1.3\040Transcriptional\040change\040of\040PPP2R5C\040in\040pathophysiology}{section.2.1}% 18
\BOOKMARK [1][]{section.2.2}{2.2\040Antibody\040and\040virus\040preparation\040for\040PPP2R5C\040study}{chapter.2}% 19
\BOOKMARK [2][]{subsection.2.2.1}{2.2.1\040Selecting\040shRNA/miRNA\040for\040efficient\040knockdown\040of\040PPP2R5C}{section.2.2}% 20
\BOOKMARK [2][]{subsection.2.2.2}{2.2.2\040Generating\040Guinea\040Pig\040antibody\040for\040endogenous\040PPP2R5C\040detection}{section.2.2}% 21
\BOOKMARK [1][]{section.2.3}{2.3\040PPP2R5C\040negatively\040regulates\040glycolysis\040and\040lipogenesis}{chapter.2}% 22
\BOOKMARK [2][]{subsection.2.3.1}{2.3.1\040PPP2R5C\040KD\040in\040Hepa\0401-6\040increases\040glycolysis}{section.2.3}% 23
\BOOKMARK [2][]{subsection.2.3.2}{2.3.2\040PPP2R5C\040KD\040promotes\040glucose\040uptake\040rate\040in\040Hepa\0401-6}{section.2.3}% 24
\BOOKMARK [2][]{subsection.2.3.3}{2.3.3\040PPP2R5C\040deficiency\040promotes\040de\040novo\040lipogenesis}{section.2.3}% 25
\BOOKMARK [1][]{section.2.4}{2.4\040PPP2R5C\040in\040vivo\040knockdown\040promotes\040glucose\040uptake,\040triglyceride\040synthesis}{chapter.2}% 26
\BOOKMARK [2][]{subsection.2.4.1}{2.4.1\040PPP2R5C\040knockdown\040has\040no\040impact\040on\040animal\040health}{section.2.4}% 27
\BOOKMARK [2][]{subsection.2.4.2}{2.4.2\040PPP2R5C\040KD\040promotes\040glucose\040uptake\040in\040vivo\040with\040better\040insulin\040sensitivity}{section.2.4}% 28
\BOOKMARK [2][]{subsection.2.4.3}{2.4.3\040PPP2R5C\040KD\040promotes\040anabolic\040changes\040in\040liver}{section.2.4}% 29
\BOOKMARK [1][]{section.2.5}{2.5\040PPP2R5C\040negatively\040regulates\040VLDL\040secretion\040in\040the\040liver}{chapter.2}% 30
\BOOKMARK [1][]{section.2.6}{2.6\040PPP2R5C's\040substrates\040in\040metabolism\040control}{chapter.2}% 31
\BOOKMARK [2][]{subsection.2.6.1}{2.6.1\040PPP2R5C's\040substrates\040include\040multiple\040metabolic\040regulators}{section.2.6}% 32
\BOOKMARK [2][]{subsection.2.6.2}{2.6.2\040AMPK\040is\040PPP2R5C's\040substrate\040involved\040in\040glucose\040uptake}{section.2.6}% 33
\BOOKMARK [2][]{subsection.2.6.3}{2.6.3\040HIF1a\040is\040PPP2R5C's\040substrate\040involved\040in\040glycolysis\040and\040lipogenesis}{section.2.6}% 34
\BOOKMARK [2][]{subsection.2.6.4}{2.6.4\040Microarray\040analysis\040of\040PPP2R5C\040KD\040in\040mouse\040liver}{section.2.6}% 35
\BOOKMARK [2][]{subsection.2.6.5}{2.6.5\040SREBP-1\040is\040involved\040in\040lipogenesis\040phenotype}{section.2.6}% 36
\BOOKMARK [1][]{section.2.7}{2.7\040Human\040PPP2R5C\040in\040Type\0402\040Diabetes}{chapter.2}% 37
\BOOKMARK [2][]{subsection.2.7.1}{2.7.1\040PPP2R5C's\040misregulation\040in\040human\040liver}{section.2.7}% 38
\BOOKMARK [2][]{subsection.2.7.2}{2.7.2\040PPP2R5C's\040misregulation\040in\040human\040adipose\040tissues}{section.2.7}% 39
\BOOKMARK [0][]{chapter.3}{3\040Discussions}{}% 40
\BOOKMARK [1][]{section.3.1}{3.1\040PPP2R5C\040in\040liver\040metabolism}{chapter.3}% 41
\BOOKMARK [1][]{section.3.2}{3.2\040PPP2R5C\040substrates}{chapter.3}% 42
\BOOKMARK [1][]{section.3.3}{3.3\040PPP2R5C's\040metabolic\040control\040in\040cancer\040cells}{chapter.3}% 43
\BOOKMARK [1][]{section.3.4}{3.4\040PPP2R5C\040in\040human\040metabolic\040diseases}{chapter.3}% 44
\BOOKMARK [0][]{chapter.4}{4\040Methodology}{}% 45
\BOOKMARK [1][]{section.4.1}{4.1\040Molecular\040Biology}{chapter.4}% 46
\BOOKMARK [2][]{subsection.4.1.1}{4.1.1\040DNA\040digestion\040by\040restriction\040enzymes}{section.4.1}% 47
\BOOKMARK [2][]{subsection.4.1.2}{4.1.2\040Polymerase\040chain\040reaction\040\(PCR\)}{section.4.1}% 48
\BOOKMARK [2][]{subsection.4.1.3}{4.1.3\040Agarose\040gel\040electrophoresis}{section.4.1}% 49
\BOOKMARK [2][]{subsection.4.1.4}{4.1.4\040Agarose\040gel\040purification}{section.4.1}% 50
\BOOKMARK [2][]{subsection.4.1.5}{4.1.5\040DNA\040ligation}{section.4.1}% 51
\BOOKMARK [2][]{subsection.4.1.6}{4.1.6\040Transformation\040of\040E.\040coli}{section.4.1}% 52
\BOOKMARK [2][]{subsection.4.1.7}{4.1.7\040Bacteria\040cultivation\040and\040plasmid\040purification}{section.4.1}% 53
\BOOKMARK [2][]{subsection.4.1.8}{4.1.8\040Cloning\040and\040selection\040of\040shRNA\040or\040miRNA\040candidates}{section.4.1}% 54
\BOOKMARK [2][]{subsection.4.1.9}{4.1.9\040Cloning\040miR30-based\040shRNA\040for\040the\040inducible\040piggyBac\040shRNA\040system}{section.4.1}% 55
\BOOKMARK [1][]{section.4.2}{4.2\040Gene\040expression\040analysis}{chapter.4}% 56
\BOOKMARK [2][]{subsection.4.2.1}{4.2.1\040Tissue\040pulverization}{section.4.2}% 57
\BOOKMARK [2][]{subsection.4.2.2}{4.2.2\040RNA\040isolation\040from\040tissue\040sample}{section.4.2}% 58
\BOOKMARK [2][]{subsection.4.2.3}{4.2.3\040RNA\040isolation\040from\040cell\040sample}{section.4.2}% 59
\BOOKMARK [2][]{subsection.4.2.4}{4.2.4\040cDNA\040synthesis}{section.4.2}% 60
\BOOKMARK [2][]{subsection.4.2.5}{4.2.5\040Quantitative\040PCR\040\(qPCR\)\040analysis}{section.4.2}% 61
\BOOKMARK [2][]{subsection.4.2.6}{4.2.6\040Microarray\040analysis\040of\040mouse\040tissue\040and\040cell\040sample}{section.4.2}% 62
\BOOKMARK [1][]{section.4.3}{4.3\040Cell\040biology}{chapter.4}% 63
\BOOKMARK [2][]{subsection.4.3.1}{4.3.1\040Cell\040culture\040for\040Hepa\0401-6,\040HEK293T,\040HEK293A,\040Hela\040Cells}{section.4.3}% 64
\BOOKMARK [2][]{subsection.4.3.2}{4.3.2\040Transfection\040assay}{section.4.3}% 65
\BOOKMARK [2][]{subsection.4.3.3}{4.3.3\040Mouse\040primary\040hepatocyte\040cultivation}{section.4.3}% 66
\BOOKMARK [2][]{subsection.4.3.4}{4.3.4\040PP2A\040substrate\040trapping\040in\040Hepa\0401-6}{section.4.3}% 67
\BOOKMARK [2][]{subsection.4.3.5}{4.3.5\040Luciferase\040assay}{section.4.3}% 68
\BOOKMARK [2][]{subsection.4.3.6}{4.3.6\040Inducible\040shRNA\040stable\040cell\040line\040generation}{section.4.3}% 69
\BOOKMARK [2][]{subsection.4.3.7}{4.3.7\040FACS\040analysis\040of\0402NBDG\040uptake}{section.4.3}% 70
\BOOKMARK [1][]{section.4.4}{4.4\040Virus\040production\040for\040mouse\040in\040vivo\040knock-down}{chapter.4}% 71
\BOOKMARK [2][]{subsection.4.4.1}{4.4.1\040shRNA\040packaging\040Adenovirus\040construction\040and\040production}{section.4.4}% 72
\BOOKMARK [2][]{subsection.4.4.2}{4.4.2\040miRNA\040packaging\040Adeno-Associated\040Virus\040construction\040and\040production}{section.4.4}% 73
\BOOKMARK [1][]{section.4.5}{4.5\040Metabolite\040measurement\040in\040celluar\040and\040tissue\040samples}{chapter.4}% 74
\BOOKMARK [2][]{subsection.4.5.1}{4.5.1\040Glucose\040consumption\040in\040Hepa\0401-6\040and\040primary\040hepatocytes}{section.4.5}% 75
\BOOKMARK [2][]{subsection.4.5.2}{4.5.2\040Lactate\040production}{section.4.5}% 76
\BOOKMARK [2][]{subsection.4.5.3}{4.5.3\040Free\040fatty\040acid\040measurement}{section.4.5}% 77
\BOOKMARK [2][]{subsection.4.5.4}{4.5.4\040Triglyceride\040measurement}{section.4.5}% 78
\BOOKMARK [2][]{subsection.4.5.5}{4.5.5\040Cholesterol\040measurement}{section.4.5}% 79
\BOOKMARK [2][]{subsection.4.5.6}{4.5.6\040Glycogen\040content\040determination}{section.4.5}% 80
\BOOKMARK [2][]{subsection.4.5.7}{4.5.7\040Ketone\040body\040measurement}{section.4.5}% 81
\BOOKMARK [2][]{subsection.4.5.8}{4.5.8\040ATP\040measurement}{section.4.5}% 82
\BOOKMARK [2][]{subsection.4.5.9}{4.5.9\040Intraperitoneal\040glucose\040tolerance\040test\040\(IPGTT\)}{section.4.5}% 83
\BOOKMARK [2][]{subsection.4.5.10}{4.5.10\040Serum\040insulin\040measurement}{section.4.5}% 84
\BOOKMARK [2][]{subsection.4.5.11}{4.5.11\040Serum\040lipoprotein\040particle\040analysis}{section.4.5}% 85
\BOOKMARK [2][]{subsection.4.5.12}{4.5.12\040Serum\040ALT\040measurement}{section.4.5}% 86
\BOOKMARK [2][]{subsection.4.5.13}{4.5.13\040Seahorse\040analysis\040of\040glycolysis\040in\040Hepa\0401-6}{section.4.5}% 87
\BOOKMARK [1][]{section.4.6}{4.6\040Biochemical\040methods}{chapter.4}% 88
\BOOKMARK [2][]{subsection.4.6.1}{4.6.1\040Protein\040expression\040in\040bacteria}{section.4.6}% 89
\BOOKMARK [2][]{subsection.4.6.2}{4.6.2\040Antibody\040production\040and\040purification}{section.4.6}% 90
\BOOKMARK [2][]{subsection.4.6.3}{4.6.3\040SDS-PAGE\040and\040western\040blot}{section.4.6}% 91
\BOOKMARK [2][]{subsection.4.6.4}{4.6.4 Phos-tag® analysis of phosphorylated proteins}{section.4.6}% 92
\BOOKMARK [2][]{subsection.4.6.5}{4.6.5\040Immunoprecipitation}{section.4.6}% 93
\BOOKMARK [1][]{section.4.7}{4.7\040Animal\040experiments}{chapter.4}% 94
\BOOKMARK [1][]{section.4.8}{4.8\040Data\040analysis\040and\040plotting}{chapter.4}% 95
\BOOKMARK [0][]{appendix.A}{A\040Materials}{}% 96
\BOOKMARK [1][]{section.A.1}{A.1\040Chemicals\040and\040kits}{appendix.A}% 97
\BOOKMARK [1][]{section.A.2}{A.2\040Antibodies}{appendix.A}% 98
\BOOKMARK [1][]{section.A.3}{A.3\040Instruments}{appendix.A}% 99
\BOOKMARK [1][]{section.A.4}{A.4\040Solutions\040and\040buffers}{appendix.A}% 100
\BOOKMARK [1][]{section.A.5}{A.5\040Primer\040list\040for\040quantitative\040RT-PCR}{appendix.A}% 101
\BOOKMARK [1][]{section.A.6}{A.6\040shRNA/miRNA\040target\040sequences}{appendix.A}% 102
\BOOKMARK [1][]{section.A.7}{A.7\040Software\040list}{appendix.A}% 103
\BOOKMARK [0][]{appendix.B}{B\040Supplementary\040Table}{}% 104
\BOOKMARK [1][]{section.B.1}{B.1\040Enriched\040TFs\040in\040mouse\040cell\040lines\040upon\040PPP2R5C\040KD}{appendix.B}% 105
\BOOKMARK [1][]{section.B.2}{B.2\040Enriched\040TFs\040in\040mouse\040liver\040upon\040PPP2R5C\040KD}{appendix.B}% 106
\BOOKMARK [2][]{subsection.B.2.1}{B.2.1\040Enriched\040TFs\040in\040mouse\040liver\040during\040fasting}{section.B.2}% 107
\BOOKMARK [2][]{subsection.B.2.2}{B.2.2\040Enriched\040TFs\040in\040mouse\040liver\040during\040ad\040libitum\040feeding}{section.B.2}% 108
\BOOKMARK [0][]{appendix*.78}{Bibliography}{}% 109
\BOOKMARK [0][]{section*.79}{Glossary}{}% 110
